CCL22 and neoplasm: suggested that anti-CCR4 antibodies can selectively deplete effector Treg cells and increases tumour antigen-specific CD4+ and CD8+ T cells (116); an in vitro study using the antibody to neutralise CCL22 blocked Tregs migration to tumour tissue (59).